Cover Image

Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series

Abstract Regulatory agencies require evidence that endpoints correlate with clinical benefit before they can be used to approve drugs. Biomarkers are often considered surrogate endpoints. In cancer cachexia trials, the measurement of biomarkers features frequently. The aim of this systematic review...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael S. Yule (Author), Joshua Thompson (Author), Khachonphat Leesahatsawat (Author), Mariana S. Sousa (Author), Stefan D. Anker (Author), Jann Arends (Author), Trude R. Balstad (Author), Leo R. Brown (Author), Asta Bye (Author), Olav Dajani (Author), Marie Fallon (Author), Marianne J. Hjermstad (Author), Gunnhild Jakobsen (Author), James McDonald (Author), Josh McGovern (Author), Eric J. Roeland (Author), Judith Sayers (Author), Richard J.E. Skipworth (Author), Inger O. Ottestad (Author), Iain Philips (Author), Melanie R. Simpson (Author), Tora S. Solheim (Author), Ola Magne Vagnildhaug (Author), Donald McMillan (Author), Barry J.A. Laird (Author), Ross D. Dolan (Author), the Cancer Cachexia Endpoints Working Group (Author)
Format: Book
Published: Wiley, 2024-06-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items